Cargando…
Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial
BACKGROUND: Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased morta...
Autores principales: | Rosso-Fernández, Clara, Garnacho-Montero, José, Antonelli, Massimo, Dimopoulos, George, Cisneros, José Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374401/ https://www.ncbi.nlm.nih.gov/pubmed/25872790 http://dx.doi.org/10.1186/s13063-015-0614-4 |
Ejemplares similares
-
Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial
por: Cisneros, José M., et al.
Publicado: (2019) -
Seventh Annual Report of the Royal Commission
Publicado: (1884) -
Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin
por: Álvarez-Marín, Rocío, et al.
Publicado: (2016) -
Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
por: Park, So Yeon, et al.
Publicado: (2019) -
Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)